Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab with medium-dose hypofractionated radiotherapy after anti-PD-1 failure in metastatic NSCLC
2020-001097-29Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoint: Safety. Started Jul 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-001097-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001097-29.